Molecular biology of bone remodelling

Clinical Cases in Mineral and Bone Metabolism

Volumn 5, Issue 1, 2008, Pages 49-56

  Rucci, Nadia ^a,b  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Bone remodelling; Osteoblast; Osteoclast; Osteoimmunology

Indexed keywords

BETA CATENIN; BETA INTERFERON; CATHEPSIN K; FIBROBLAST GROWTH FACTOR; GELATINASE B; INTERLEUKIN 1; INTERLEUKIN 6; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE; PROCOLLAGEN C PROTEINASE; SOMATOMEDIN C; TRANSCRIPTION FACTOR OSTERIX; TRANSCRIPTION FACTOR RUNX2; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; WNT PROTEIN;

ALBERS SCHOENBERG DISEASE; BONE MASS; BONE REMODELING; CELL FUNCTION; IMMUNE SYSTEM; MESENCHYMAL STEM CELL; MOLECULAR BIOLOGY; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RHEUMATOID ARTHRITIS; SHORT SURVEY;

EID: 45349091141     PISSN: 17248914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (96)

1. Zaidi M. Skeletal remodelling in health and disease. Nature Med. 2007; 13:791-801.
2. Cohen MM. The new bone biology: pathologic, molecular and clinical correlates. Am J Med Genetics. 2006;140A:2646-2706.
3. Nijweide PJ, Burger EH, Klein Nulend J, et al..The osteocyte. In: Bilezikian JP, Raisz LG, Rodan GA eds. Principles of bone biology. London UK: Academic Press; 1996:115-126.
4. Grigoriadis AE, Heersche JN, Aubin JE. Differentiation of muscle, fat, cartilage, and bone from progenitor cells present in a bone derived clonal cell population: effect of dexamethasone. J Cell Biol. 1988;106:2139-2151.
5. Yamaguchi A, Khan AJ. Clonal osteogenic cell lines express myogenic and adipocytic developmental potential. Calcif Tissue Int. 1991;49:221-225.
6. Bennett CN, Longo KA, Wright WS, et al. Regulation of osteoblastogenesis and bone mass by Wnt 10b. Proc Natl Acad Sci USA. 2005;102:3324-3329.
7. Gaur T, Lengner CJ, Hovhannisyan H, et al. Canonical WNT signalling promotes osteogenesis by directly stimulating RUNX2 gene expression. J Biol Chem. 2005;280:33132-33140.
8. Glass DA II and Karsenty G. Minireview: In vivo analysis of Wnt signalling in bone. Endocrinology. 2007;148:2630-2634.
9. Nakashima K, de Crombrugghe B. Transcriptional mechanisms in osteoblast differentiation and bone formation. Trends Genet. 2003; 19:458-466.
10. Ducy P, Zhang R, Geoffroy V, et al. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell. 1997;89:747-754.
11. Karsenty G, Wagner EF. Reaching a genetic and molecular understanding of skeletal development. Dev Cell. 2002;2:389-406.
12. Olsen BR, Reginato AM, Wang W. Bone development. Ann Rev Cell Dev Biol. 2000;16:191-220.
13. Ducy P, Starbuck M, Priemel M, et al. Cbfa1-dependent genetic pathway controls bone formation beyond embryonic development. Genes and Development 1999;13:1025-1036.
14. Liu W, Toyosawa S, Furuichi T, et al. Overexpression of Cbfa1 in osteoblasts inhibits osteoblast maturation and causes osteopenia with multiple fractures. J Cell Biol. 2001;155:157-166.
15. Lee B, Thirunavukkarasu K, Zhou L, et al. Missense mutations abolishing DNA binding of the osteoblast-specific transcription factor OSF2/CBFA1 in cleidocranial dysplasia. Nat Genet. 1997;16: 307-310.
16. Mundlos S, Olsen BR. Heritable diseases of the skeleton. Part II: molecular insights into skeletal development-matrix components and their homeostasis. FASEB J. 1997;11:227-233.
17. Kaneki H, Guo R, Chen D, et al. TNF promotes RUNX2 degradation through up-regulation of SMURF1 and SMURF2 in osteoblasts. J Biol Chem. 2006;281:4326-4333.
18. Nakashima K, Zhou X, Kunkel G, et al. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell. 2002;108:17-29.
19. Koga T, Matsui Y, Asagiri M, et al. NFAT and Osterix cooperatively regulate bone formation. Nat Med. 2005;11:880-885.
20. Westendorf JJ, Kahler RA and Schroeder TM. Wnt signalling in osteoblasts and bone diseases. Gene. 2004;341:19-39.
21. Rawadi G and Roman-Roman S. Wnt signalling pathways: a new target for the treatment of osteoporosis. Exp Opin Ther Targets. 2005;9:1063-1077.
22. Gong Y, Slee RB, Fuki N, et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell. 2001; 107:513-523.
23. Boyden LM, Mao J, Belsky J, et al. High bone density due to a mutation in LDL-receptor-related protein 5. New Engl J Medicine. 2002;346:1513-1521.
24. Van Wesenbeeck L, Cleiren E, Gram J, et al. Six novel missense mutations in the LDL receptor-related proteins (LRP5) gene in different conditions with increased bone density. Am J Human Genet. 2003;72:763-771.
25. Clevers H. Wnt/b-catenin signalling in development and disease. Cell. 2006;127:469-480.
26. Hay E, Faucheu C, Suc-Royer I, et al. Interaction between LRP5 and Frat1 mediates the activation of the Wnt canonical pathway. J Biol Chem. 2005;280:13616-13623.
27. Baron R and Rawadi G. Minireview: targeting the Wnt/β-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology. 2007;148:2635-2643.
28. Mao B, Wu W, Davidson G, et al. Kremen proteins are Dickkopf receptors that regulate Wnt/beta-catenin signalling. Nature. 2002; 417:664-667.
29. Kingsley DM, Bland AE, Grubber JM, et al. The mouse short ear skeletal morphogenesis locus is associated with defects in a bone morphogenetic member of the TGF beta superfamily. Cell. 1992; 71:399-410.
30. Storm EE, Huynh TV, Copeland NG, et al. Limb alterations in brachypodism mice due to mutations in a new member of the TGF beta-superfamily. Nature. 1994;368:639-643.
31. Thomas JT, Kilpatrick MW, Lin K, et al. Disruption of human limb morphogenesis by a dominant negative mutation in CDMP1. Nat Genet. 1997;17:58-64.
32. Yamaguchi A, Komori T, Suda T. Regulation of osteoblast differentiation mediated by bone morphogenetic proteins, hedgehogs, and Cbfa1. Endocr Rev. 2000;21:393-411.
33. Yamashita T, Ishii H, Shimoda K, et al. Subcloning of three osteoblastic cell lines with distinct differentiation phenotypes from the mouse osteoblastic cell line KS-4. Bone. 1996;19:429-436.
34. Walker DG. Bone resorption restored in osteopetrotic mice by transplants of normal bone marrow and spleen cells. Science. 1975;190:784-785.
35. Udagawa N, Takahashi N, Akatsu T, et al. Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. Proc Natl Acad Sci. USA. 1990;87:7260-7264.
36. Arai F, Miyamoto T, Ohneda O, et al. Commitment and differentiation of osteoclast precursor cells by sequential expression of c-Fms and receptor activator of nuclear kappaB (RANK) receptors. J Exp Med. 1999;190:1741-1754.
37. Galibert L, Tometsko ME, Anderson DM, et al. The involvement of multiple tumour necrosis factor receptor (TNFR)-associated factors in the signalling mechanisms of receptor activator of NF-κB, a member of the TNFR superfamily. J Biol Chem. 1998;273:34120-34127.
38. Darnay BG, NI J, Moore PA, et al. Activation of NF-κB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and activation of NF-κB inducing kinase. Identification of a novel TRAF6 interaction motif. J Biol Chem. 1999;274:7724-7731.
39. Gohda J, Akiyama T, Koga T, et al. RANK-mediated amplification of TRAF6 signaling leads to NFATc1 induction during osteoclastogenesis. EMBO J. 2005;24:790-799.
40. Lomaga MA, Yeh WC, Sarosi I, et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1. CD40, and LPS signalling. Genes Dev. 1999;13:1015-1024.
41. Naito A, Azuma S, Tanaka S, et al. Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice. Genes Cells. 1999;4:353-362.
42. Kobayashi N, Kadono Y, Naito A, et al. Segregation of TRAF6-mediated signalling pathwavs clarifies its role in osteoclastogenesis. EMBO J. 2001;20:1271-1280.
43. Takayanagi H, Ogasawara K, Mida S, et al. T cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ. Nature 2000;408:600-605.
44. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003;423:337-342.
45. Li F, Matsuo K, Xing L, et al. Over-expression of activated NFATc1 plus RANKL rescues the osteoclastogenesis defect of NF-κB p50/p52 double knockout splenocytes. J Bone Miner Res. 2004;19:S2.
46. Takatsuna H, Asagiri M, Kubota T, et al. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-κB inhibitor, through downregulation of NFATc1. J Bone Miner Res. 2005;20: 653-662.
47. Asagiri M, Sato K, Usami T, et al. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J Exp Med. 2005;202:1261-1269.
48. Wang ZQ, Ovitt C, Grigoriadis AE, et al. Bone and haematopoietic defects in mice lacking c-fos. Nature. 1992;360:741-745.
49. Takayanagi H, Kim S, Koga T, et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signalling for terminal differentiation of osteoclasts. Dev Cell. 2002;3:889-901.
50. Matsuo K, Galson DL, Zhao C, et al. Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos. J Biol Chem. 2004;279:26475-26480.
51. Teitelbaum SL. Osteoclasts: what do they do and how do they do it? Am J Pathol. 2007;170:427-435.
52. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89:309-319.
53. Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nature. 2007; 7:292-304.
54. Walsh MC, Kim N, Kadono Y, et al. Osteoimmunology: interplay between the immune system and bone metabolism. Ann Rev Immunol. 2006;24:33-63.
55. Sato K and Takayanagi H. Osteoclast, rheumatoid arthritis and osteoimmunology. Curr Opin Rheumatol. 2006;18:419-426.
56. Koga T, Inui M, Inoue K, et al. Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature. 2004;428:758-763.
57. Mocsai A, Humphrey MB, Van Ziffle JA, et al. The immunomodulatory adapter proteins DAP12 and Fc receptor γ chain (FcRg) regulate development of functional osteoclasts through the Syk tyrosine kinase. Proc Natl Acad Sci USA 2004;101:6158-6163.
58. Suda T, Takahashi N, Udagawa N, et al. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev. 1999; 20:345-357.
59. Azuma Y, Kaji K, Katogi R, et al. Tumor necrosis factor-α induces differentiation of and bone resorption by osteoclasts. J Biol Chem. 2000;275:4858-4864.
60. Kobayashi K, Takahashi N, Jimi E, et al. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med. 2000;191: 275-286.
61. Kim N, Kadono Y, Takami M, et al., Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis. J Exp Med. 2005; 202:589-595.
62. Takayanagi H, Kim S, Matsuo K, et al. RANKL maintains bone homeostasis through c-Fos dependent induction of interferon-β. Nature 2002;416:744-749.
63. Baron R, Neff L, Louvard D, et al. Cell-mediated extracellular acidification and bone resorption: evidence for a low pH in resorbing lacunae and localization of a 100-kD lysosomal membrane protein at the osteoclast ruffled border. J Cell Biol. 1985;101:2210-2222.
64. Tuukkanen J, Väänänen HK. Omeprazole, a specific inhibitor of H+-K+-ATPase, inhibits bone resorption in vitro. Calcif Tissue Int. 1986;38:123-125.
65. Teti A, Marchisio PC, Zallone AZ. Clear zone in osteoclast function: role of podosomes in regulation of bone-resorbing activity. Am J Physiol. 1991;261:C1-C7.
66. McHugh KP, Hodivala-Dilke K, Zheng MH, et al. Mice lacking β3 integrins are osteosclerotic because of dysfunctional osteoclasts. J Clin Invest. 2000;105:433-440.
67. Blair HC, Teitelbaum SL, Ghiselli R, et al. Osteoclastic bone resorption by a polarized vacuolar proton pump. Science. 1989;245: 855-857.
68. Väänänen HK, Karhukorpi EK, Sundquist K, et al. Evidence for the presence of a proton pump of the vacuolar H(+)-ATPase type in the ruffled borders of osteoclasts. J Cell Biol. 1990;111:1305-1311.
69. Bekker PJ, Gay CV. Biochemical characterization of an electrogenic vacuolar proton pump in purified chicken osteoclast plasma membrane vesicles. J Bone Miner Res. 1990;5:569-579.
70. Frattini A, Orchard PJ, Sobacchi C, et al. Defects in TCIRG1 subunit of the vacuolar proton pump are responsible for a subset of human autosomal recessive osteopetrosis. Nature Genet. 2000; 25:343-346.
71. Kornak U, Schulz A, Friedrich W, et al. Mol Genet. 2000;9:2059-2063.
72. Sundquist KT, Leppilampi M, Järvelin K, et al. Carbonic anhydrase isoenzymes in isolated rat peripheral monocytes, tissue macrophages, and osteoclasts. Bone. 1987;8:33-38.
73. Teti A, Blair HC, Teitelbum SL, et al. Cytoplasmic pH regulator and chloride/bicarbonate exchange in avian osteoclasts. J Clin Invest. 1989;83:227-233.
74. Blair HC, Schlesinger PH. Purification of a stilbene sensitive chloride channel and reconstitution of chloride conductivity into phospholipid vesicles. Biochem Biophys Res Commun. 1990;171:920-925.
75. Schlesinger PH, Blair HC, Teitelbaum SL, et al. Characterization of the osteoclast ruffled border chloride channel and its role in bone resorption. J Biol Chem. 1997;272:18636-18643.
76. Kornak U, Kasper D, Bosl MR, et al. Loss of the CIC-7 chloride channel leads to osteopetrosis in mice and man. Cell. 2001;104: 205-215.
77. Saftig P, Hunziker E, Wehmeyer O, et al. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci. USA 1998;95:13453-13458.
78. Gowen M, Lazner F, Dodds R, et al. Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J Bone Miner Res. 1999;14:1654-1663.
79. Gelb BD, Shi GP, Chapman HA, et al. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 1996; 273:1236-1238.
80. Johnson MR, Polymeropoulos MH, Vos HL, et al. A nonsense mutation in the cathepsin K gene observed in a family with pycnodysostosis. Genome Res. 1996;6:1050-1055.
81. Andersen TL, del Carmen Ovejero M, Kirkegaard T, et al. A scrutiny of matrix metalloproteinases in osteoclasts: evidence for heterogeneity and for the presence of MMPs synthesized by other cells. Bone 2004;3:1107-1119.
82. Linsuwanont-Santiwong B, Takagi Y, Ohya K, et al. Expression of MT1-MMP during deciduous tooth resorption in odontoclasts. J Bone Miner Metab. 2006;24:447-453.
83. Broomley M and Woolley DE. Chondroclasts and osteoclasts at subchondral sites of erosion in rheumatoid joint. Arthritis Rheum. 1984;27:968-975.
84. Kong YY, Feige U, Sarosi I, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature. 1999;402:304-309.
85. Takayanagi H, Huji T, Miyazaki T, et al. Suppression of arthritic bone destruction by adenovirus-mediated csk gene transfer to synoviocytes and osteoclasts. J Clin Invest. 1999;104:137-146.
86. Takayanagi H. Inflammatory bone destruction and osteoimmunology. Curr Opin Rheumatol. 2006;18:419-426.
87. Whyte MP. Osteopetrosis. In: Royce PM, Steinamann B, eds. Connective tissue and its heritable disorders: medical, genetic and molecular aspects. New York, Wiley-Liss Inc. 2002:753-770.
88. Frattini A, Pangrazio A, Susani L, et al. Chloride channel CICN7 mutations are responsible for severe recessive, dominant and intermediate osteopetrosis. J Bone Miner Res. 2003;18:1740-1747.
89. Lange PF, Wartosch L, Jentsch TJ, et al. CIC-7 requires Ostm1 as a beta-subunit to support bone resorption and lysosomal function. Nature. 2006;440:220-223.
90. Chalhoub N, Benachenhou N, Raiapurohitam V, et al. Grey-lethal mutation induces severe malignant autosomal recessive osteopetrosis in mouse and human. Nat Med. 2003;9:399-406.
91. Pangrazio A, Poliani PL, Megarbane A, et al. Mutation in OSTM1 (grey lethal) define a particularly severe form of autosomal recessive osteopetrosis with neural involvement. J Bone Miner Res. 2006;21:1098-1105.
92. Sobacchi C, Frattini A, Guerrini MM, et al. Osteoclast-poor human osteopetrosis due to mutation in the gene encoding RANKL. Nat Genet. 2007;39:960-962.
93. Bolt RJ, Wennink JM, Verbeke JI, et al. Carbonic anhydrase type II deficiency. Am J Kidney Dis. 2005;46:A50,e71-3.
94. Van Wesenbeeck L, Odgren PR, Coxon FP, et al. Involvement of PLEKHM1 in osteoclastic vesicular transport and osteopetrosis in incisors absent rats and humans. J Clin Invest. 2007;117:919-930.
95. Albers-Schönberg HE. Röntgenbilder einer seltenen Knockenerkrankung. Munch Med Wochenschr. 1904;5:365-368.
96. Del Fattore A, Cappariello A, Teti A. Genetics, pathogenesis and complications of osteopetrosis. Bone. 2008;42:19-29.